The Development Programs (Career Development Program [CDP] and the Developmental Research Program [DRP]) are components of the multi-institutional Developmental and Hyperactive Ras Tumor (DHART) SPORE. The primary focus of this SPORE is to improve the diagnosis and management of tumors arising in persons with neurofibromatosis type 1 (NF1) and other inherited “Rasopathy” syndromes through basic, translational, and clinical research. These tumors include plexiform neurofibroma, malignant peripheral nerve sheath tumor (MPNST), optic track glioma, juvenile myelomonocytic leukemia (JMML), and subsequent malignant neoplasms caused by prior exposure to mutagenic chemotherapy and/or radiation.

Please direct any questions about the CDP/DRP to Kevin Shannon, MD, University of California: Kevin.Shannon@ucsf.edu.

Career Development Program (CDP)

The goals of the CDP are: (1) to attract outstanding young basic scientists and clinical investigators to the field of NF1-associated tumor research; (2) to assist in the career development of these junior faculty; and, (3) to encourage collaborations between investigators which can lead to new ideas and directions in research related to tumors associated with NF1 mutations and can contribute to career development. Research proposals investigating the role of somatic NF1 mutations in cancers such as glioblastoma multiforme, adenocarcinoma of the lung, melanoma, and myeloid leukemia will also be considered for support through this program.

Eligibility

CDP proposals will be accepted from clinical or basic science investigators at any DHART SPORE institution (Indiana University, University of California, San Fransisco, Memorial Sloan-Kettering Cancer Center, University of Texas Southwestern, University of Alabama, Birmingham, University of North Carolina, and Johns Hopkins). Application is limited to faculty who are scientifically independent by the criteria of eligibility to apply for NIH R01 awards, but who do not currently hold R01 or equivalent funding for NF1-related research. Faculty members with NIH career development awards (K08; K23) are encouraged to apply for CDP funds. Faculty members from under-represented in medicine (URM) groups are strongly encouraged to apply.

Developmental Research Program (DRP)

The DRP supports innovative pilot projects to advance the diagnosis and treatment of early stage tumors and advanced cancers characterized by germline and somatic NF1 mutations. Research proposals investigating the role of somatic NF1 mutations in cancers such as glioblastoma multiforme, adenocarcinoma of the lung, melanoma, and myeloid leukemia will also be considered for support through this program. The DRP will accomplish this goal by funding rigorous translational research in the areas of population science, therapeutics, and mechanisms of disease and by facilitating collaborative interactions between DRP-funded scientists and other SPORE investigators.

Eligibility

DRP Proposals will be accepted from clinical or basic science investigators at any DHART SPORE institution Indiana University, University of California, San Fransisco, Memorial Sloan-Kettering Cancer Center, University of Texas Southwestern, University of Alabama, Birmingham, University of North Carolina, and Johns Hopkins). Application is limited to faculty who are scientifically independent by the criteria of eligibility to apply for NIH R01 awards, but who do not currently hold R01 or equivalent funding for NF1-related research. Faculty members with NIH career development awards (K08; K23) are not eligible to apply for DRP funds. Faculty members from under-represented in medicine (URM) groups are strongly encouraged to apply.